newsfilter
← Latest News
GlobeNewswire·

ArriVent BioPharma Reports First Quarter 2024 Financial Results

Presented preclinical firmonertinib (formerly furmonertinib) data at the 2024 American Association for Cancer Research ("AACR") Annual MeetingDosed first patient in Phase 1b combination study of firmonertinib and ICP-189